Medo has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Medo-Thyroid, artificial intelligence (AI) software that simplifies workflow for thyroid ultrasound scanning.
With Medo-Thyroid, users perform quick video sweeps of each side of the thyroid gland. The algorithm then uses AI to automatically review the data and select the optimal images for analysis; calculate standard lobe and isthmus measurements; and assist in locating, measuring, and characterizing any nodules present using the Thyroid Imaging Reporting and Data System (TI-RADS) system. The end result is an individualized, interactive report, according to the company.
The company previously announced the release of an AI assistant for helping diagnose hip dysplasia and is now expanding its technology into other use cases.
